Interferon alpha sequential regimen for treating cancers
The present invention relates to a method of treating cancers, especially those showing resistance to classical anti-pro liferative chemotherapy drugs. Further, the invention provides a specific interferon alpha sequential regimen for treating cancers, especially those showing resistance to classical anti-proliferative chemotherapy drugs such as stem cell driven cancers. More specifically, the invention relates to a use of IFN alpha for the preparation of a pharmaceutical formulation for the treatment of cancers wherein the pharmaceutical formulation is to be administered following a sequential administration pattern i.e. an induction period wherein a therapeutically effective amount of IFN alpha is administered, a period during which ni IFN alpha is administrated and a chemotherapy period wherein a therapeutically effective amount of a chemotherapeutic agent is administered.
39831995
Alternative title(s) : (de) Sequentielles behandlungsschema mit interferon alpha gegen krebs (fr) Régime séquentiel d'interféron alpha dans le traitement de cancers
TTO:6.0686
Patent number | Country code | Kind code | Date issued |
US8329160 | US | B2 | 2012-12-11 |
DK2205268 | DK | T3 | 2012-11-26 |
EP2205268 | EP | B1 | 2012-08-15 |
JP2010529984 | JP | A | 2010-09-02 |
US2010196320 | US | A1 | 2010-08-05 |
EP2205268 | EP | A1 | 2010-07-14 |
WO2008152609 | WO | A1 | 2008-12-18 |